Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
  • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• • G—PHYSICS
  • G07—CHECKING-DEVICES
  • G07B—TICKET-ISSUING APPARATUS; FARE-REGISTERING APPARATUS; FRANKING APPARATUS
  • G07B15/00—Arrangements or apparatus for collecting fares, tolls or entrance fees at one or more control points
• • G—PHYSICS
  • G07—CHECKING-DEVICES
  • G07B—TICKET-ISSUING APPARATUS; FARE-REGISTERING APPARATUS; FRANKING APPARATUS
  • G07B15/00—Arrangements or apparatus for collecting fares, tolls or entrance fees at one or more control points
  • G07B15/02—Arrangements or apparatus for collecting fares, tolls or entrance fees at one or more control points taking into account a variable factor such as distance or time, e.g. for passenger transport, parking systems or car rental systems
• • G—PHYSICS
  • G07—CHECKING-DEVICES
  • G07B—TICKET-ISSUING APPARATUS; FARE-REGISTERING APPARATUS; FRANKING APPARATUS
  • G07B15/00—Arrangements or apparatus for collecting fares, tolls or entrance fees at one or more control points
  • G07B15/06—Arrangements for road pricing or congestion charging of vehicles or vehicle users, e.g. automatic toll systems
  • G07B15/063—Arrangements for road pricing or congestion charging of vehicles or vehicle users, e.g. automatic toll systems using wireless information transmission between the vehicle and a fixed station

Definitions

• This document relates to compounds useful for preventing, treating or ameliorating human cytomegalovirus infection.
• HCMV Human cytomegalovirus
• Organ transplant patients under immunosuppressive therapy are at high risk for viral infections; activation of a latent virus as well as donor or community acquired primary infections can cause significant complications including graft rejection, morbidity, and mortality.
• Herpesviruses e.g. HCMV, HSV-1
• polyomaviruses e.g. BKV and JCV
• hepatitis viruses HBV and HCV
• respiratory viruses e.g. influenza A, adenovirus
• Cytomegalovirus is the most prevalent post-transplant pathogen; HCMV can infect most organs, and despite the availability of HCMV antivirals such as ganciclovir, nephrotoxic side effects and increasing rates of drug-resistance significantly reduce graft and patient survival.
• HCMV- mediated immune modulation can reactivate distinct latent viruses carried by most adults.
• the invention provides compounds having the structure of Formula I:
• each cyclic 5- or 6-membered ring in Ar optionally contains up to two
• Y is, independently in each instance, C or a bond
• Rin B is selected from the rou consistin of:
• n 0, 1 or 2
• n is, independently in each instance, 0 or 1 ,
• p 0 or 1
• R 2 is H or a lower straight or branched alkyl or alkenyl optionally substituted with one heteroatom selected of N and O,
• R 3 is H or OH
• R4 is H or a saturated 5- or 6-membered aryl or cycloalkyl with up to two heteroatoms selected from N, O and S,
• R 5 is H, -OR 7 , or -NR 6 R 7 ,
• Re and R 7 are independently selected in each instance from H and lower straight chain or branched alkyl
• X 5 is C, O, S or NR 7 ,
• Z 2 is C, O, S or NR 7 ;
• the compounds of the invention are useful for treating and/or preventing HCMV infections.
• the invention also provides methods of preventing, treating and/or ameliorating HCMV infections with compounds of Formula I.
• kits for treating or preventing a HCMV infection in a subject include administering a therapeutically effective amount of one or more of the compounds provided herein.
• the compounds provided herein can inhibit HCMV production in a cell infected with the virus. In such embodiments, the cell is contacted with a virus production inhibiting amount of one or more compounds provided herein.
• each cyclic 5- or 6-membered ring in Ar optionally contains up to two
• Y is, independently in each instance, C or a bond
• Ring B is selected from the group consisting of:
• n 0, 1 or 2
• n is, independently in each instance, 0 or 1
• p 0 or 1
• Zi is C, O, S or NR 7
• Ri is H, halo, -CN, -N0 2 , -C(0)NR6R 7 , or C(0)OR6,
• R 2 is H or a lower straight or branched alkyl or alkenyl optionally substituted with one heteroatom selected of N and O,
• R 3 is H or OH
• R4 is H or a saturated 5- or 6-membered aryl or cycloalkyl with up to two heteroatoms selected from N, O and S,
• R 5 is H, -OR 7 , or -NR 6 R 7 ,
• Re and R 7 are independently selected in each instance from H and lower straight chain or branched alkyl
• X 5 is C, O, S or NR 7 ,
• Z 2 is C, O, S or NR 7 ;
• the compounds of Formula I are useful for preventing, treating and/or ameliorating a HCMV infection.
• X ls X 2 , X 3 and X 4 are independently selected from C and N and all the other variables are as defined for Formula I,
• X ls X 2 , X 3 and X 4 are independently selected from C and N and all the other variables are as defined for Formula I,
• X ls X 2 , X 3 and X 4 are independently selected from C and N and all other variables are as defined for Formula I,
• Some embodiments of the of the anti-HCMV compounds provided herein have the structure of Formula VII, The composition of claim 1, comprising a compound of Formula VII or a pharmaceutically acceptable salt thereof:
• R4 is in the meta or para position and is selected from the group consisting of pyrrole, imidazole, pyrazole, pyrazine, pyrimidine and pyridazine.
• Ri if present in the formula, is H, halo, -CN, or -N0 2 , and R4, if present in the formula, is a saturated 5- or 6-membered aryl or cycloalkyl with up to two heteroatoms selected from N, O and S.
• the compound is selected from the group consisting of:
• Some embodiments of the method for treating or preventing a HCMV infection in a subject can include administering a therapeutically effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII or pharmaceutically acceptable salts thereof. Also provided herein is a method of inhibiting HCMV production comprising contacting a HCMV -infected cell with a virus production inhibiting amount of any of the compounds of Formulas I, II, III, IV, V, VI and VII.
• an antiviral agent can also be administered in conjunction with the compounds and the methods described herein.
• the agent can be any therapeutic agent useful in the treatment of a HCMV infection.
• an antiviral agent can include acyclovir, docosanol, ribarivin, interferons, and the like; cellulose acetate, carbopol and carrageenan, pleconaril, amantidine, rimantidine, fomivirsen, zidovudine, lamivudine, zanamivir, oseltamivir, brivudine, abacavir, adefovir, amprenavir, arbidol, atazanavir, atripla, cidofovir, combivir, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet, fosfonet, ganci
• a compound provided herein can be administered before, after, or simultaneously with the administration or one or more antiviral agents.
• a compound provided herein, including a pharmaceutically acceptable salt thereof, can be purchased commercially or prepared using known organic synthesis techniques.
• compositions which include compounds provided herein and one or more pharmaceutically acceptable carriers. Also provided herein are the compositions themselves.
• compositions typically include a pharmaceutically acceptable carrier.
• pharmaceutically acceptable carrier includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
• a pharmaceutical composition is typically formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
• solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
• the parenteral preparation can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.
• compositions suitable for injection can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
• suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
• the composition must be sterile and should be fluid to the extent that easy syringability exists.
• the composition should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
• the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
• Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
• isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition.
• Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
• Sterile injectable solutions can be prepared by incorporating a compound provided herein in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
• dispersions are prepared by incorporating a compound provided herein into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
• the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of a compound provided herein plus any additional desired ingredient from a previously sterile-filtered solution thereof.
• Oral compositions generally include an inert diluent or an edible carrier.
• a compound provided herein can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules.
• Oral compositions can also be prepared using a fluid carrier for use as a mouthwash.
• compositions can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
• a binder such as microcrystalline cellulose, gum tragacanth or gelatin
• an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
• a lubricant such as magnesium stearate or Sterotes
• a glidant such as colloidal silicon dioxide
• a sweetening agent such as sucrose or saccharin
• the compounds can be delivered in the form of an aerosol spray from a pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
• a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
• Systemic administration of a therapeutic compound as described herein can also be by transmucosal or transdermal means.
• penetrants appropriate to the barrier to be permeated are used in the formulation.
• penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
• Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
• the compounds provided herein can be formulated into ointments, salves, gels, or creams as generally known in the art.
• compositions can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
• suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
• retention enemas for rectal delivery.
• intranasal delivery is possible, as described in, inter alia, Hamajima et al, Clin. Immunol. Immunopathol, 88(2), 205-10 (1998).
• Liposomes e.g., as described in U.S. Patent No. 6,472,375
• microencapsulation can also be used.
• Biodegradable targetable microparticle delivery systems can also be used (e.g., as described in U.S. Patent No. 6,471,996).
• the therapeutic compounds are prepared with carriers that will protect the therapeutic compounds against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
• a controlled release formulation including implants and microencapsulated delivery systems.
• Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
• Such formulations can be prepared using standard techniques, or obtained commercially, e.g., from Alza Corporation and Nova Pharmaceuticals, Inc.
• Liposomal suspensions (including liposomes targeted to selected cells with monoclonal antibodies to cellular antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
• the pharmaceutical composition may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
• compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. Methods for preparation of these compositions are known to those skilled in the art.
• the contemplated compositions may contain 0.001%- 100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%.
• compositions can be included in a container, pack, or dispenser together with instructions for administration.
• the preparations of one or more compounds provided herein may be given orally, parenterally, topically, or rectally. They are, of course, given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, infusion; topically by lotion or ointment; and rectally by suppositories. In some embodiments, administration is oral.
• parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection, and infusion.
• Actual dosage levels of the active ingredients in the pharmaceutical compositions provided herein may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
• compositions provided herein can be provided in an aqueous solution containing about 0.1-10%) w/v of a compound disclosed herein, among other substances, for parenteral administration.
• Typical dose ranges can include from about 0.01 to about 50 mg/kg of body weight per day, given in 1-4 divided doses. Each divided dose may contain the same or different compounds.
• the dosage will be a therapeutically effective amount depending on several factors including the overall health of a patient, and the formulation and route of administration of the selected compound(s).
• a daily dosage of from 0.01 to 2000 mg of the compound is recommended for an adult human patient, and this may be administered in a single dose or in divided doses.
• the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.
• the precise time of administration and/or amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a particular compound, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), route of administration, etc.
• physiological condition of the patient including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication
• route of administration etc.
• the above guidelines can be used as the basis for fine-tuning the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the patient and adjusting the dosage and/or timing.
• conjoint therapy wherein one or more other therapeutic agents are administered with a compound or a pharmaceutical composition comprising a compound provided herein.
• Such conjoint treatment may be achieved by way of the simultaneous, sequential, or separate dosing of the individual components of the treatment.
• the phrase “and without limitation” is understood to follow unless explicitly stated otherwise.
• the term “about” is meant to account for variations due to experimental error. All measurements reported herein are understood to be modified by the term “about”, whether or not the term is explicitly used, unless explicitly stated otherwise.
• the singular forms "a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
• a "subject,” as used herein, includes both humans and other animals, particularly mammals. Thus, the methods are applicable to both human therapy and veterinary applications.
• the patient is a mammal, for example, a primate. In some embodiments, the patient is a human.
• a “therapeutically effective” amount of a compound provided herein is typically one which is sufficient to prevent, eliminate, ameliorate or reduce the symptoms of a HCMV infection. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease.
• a “virus production inhibiting" amount of a compound provided herein is typically one which is sufficient to achieve a measurable reduction in the amount of virus produced by the cells contacted with the compound.
• a “virus production inhibiting” amount is an amount which inhibits a least 30% of the virus production in untreated cells.
• a “virus production inhibiting” amount is an amount which inhibits a least 50% of the virus production in untreated cells.
• a “virus production inhibiting” amount is an amount which inhibits a least 70% of the virus production in untreated cells.
• a “virus production inhibiting” amount is an amount which inhibits a least 90% of the virus production in untreated cells.
• treatment and “prevention” are art-recognized and include administration of one or more of the compounds or pharmaceutical compositions provided herein. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the subject) then the treatment is preventative, (i.e., it protects the subject against developing the unwanted condition).
• prevent means to slow or prevent the onset of at least one symptom of a disorder as provided herein. For example, such prevention may be prompted by a likelihood of exposure to an infective agent (e.g., a virus) or when a subject exhibits other symptoms that indicate onset of a disorder (e.g., a metabolic disorder or cardiovascular disorder) may be likely.
• the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
• to "treat” means to ameliorate at least one symptom of a disorder as provided herein.
• a compound provided herein, or salt thereof is substantially isolated.
• substantially isolated it is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
• Partial separation can include, for example, a composition enriched in the compound provided herein.
• Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%>, at least about 80%>, at least about 90%>, at least about 95%, at least about 97%, or at least about 99% by weight of the compound provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
• phrases "pharmaceutically acceptable” is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication,
• pharmaceutically acceptable salt refers to the relatively non-toxic, inorganic and organic acid addition salts of a compound provided herein. These salts can be prepared in situ during the final isolation and purification of a compound provided herein, or by separately reacting the compound in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
• Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts, and amino acid salts, and the like.
• sulfate bisulfate
• phosphate nitrate
• acetate valerate
• oleate palmitate
• stearate laurate
• benzoate lactate
• phosphate tosylate
• citrate maleate
• fumarate succinate
• tartrate naphthylate
• mesylate glucoheptonate
• lactobionate lactobionate
• laurylsulphonate salts
• a compound provided herein may contain one or more acidic functional groups and, thus, is capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
• pharmaceutically acceptable salts refers to the relatively non-toxic inorganic and organic base addition salts of a compound provided herein. These salts can likewise be prepared in situ during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine.
• Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like.
• Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al, supra).
• alkyl refers to straight and branched chain aliphatic groups having from 1 to 12 carbon atoms, preferably 1-8 carbon atoms, and more preferably 1-6 carbon atoms, which is optionally substituted with one, two or three substituents.
• alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, tertbutyl, pentyl, and hexyl.
• a "Co” alkyl (as in “Co-C3-alkyl”) is a covalent bond (like "Co” hydrocarbyl).
• the term “lower alkyl” refers to straight and branched chain aliphatic groups having from 1 to 6 carbon atoms. Unless otherwise specified, the term “alkyl” includes alkenyl, alkynyl and cyclic alkyl groups.
• alkenyl as used herein means an unsaturated straight or branched chain aliphatic group with one or more carbon-carbon double bonds, having from 2 to 12 carbon atoms, preferably 2-8 carbon atoms, and more preferably 2-6 carbon atoms, which is optionally substituted with one, two or three substituents.
• Preferred alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.
• alkynyl as used herein means an unsaturated straight or branched chain aliphatic group with one or more carbon-carbon triple bonds, having from 2 to 12 carbon atoms, preferably 2-8 carbon atoms, and more preferably 2-6 carbon atoms, which is optionally substituted with one, two or three substituents.
• Preferred alkynyl groups include, without limitation, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
• heteroalkyl refers to an alkyl group, as defined herein above, wherein one or more carbon atoms in the chain are replaced by a heteratom selected from the group consisting of O, S, and N.
• aryl group is a C 6 -Ci4 aromatic moiety comprising one to three aromatic rings, which is optionally substituted.
• the aryl group is a C 6 -Cio aryl group.
• Preferred aryl groups include, without limitation, phenyl, naphthyl, anthracenyl, and fluorenyl.
• a “heterocyclyl” or “heterocyclic” group is a ring structure having from about 3 to about 8 atoms, wherein one or more atoms are selected from the group consisting of N, O, and S.
• the heterocyclic group is optionally substituted on carbon at one or more positions.
• the heterocyclic group is also independently optionally substituted on nitrogen with alkyl, aryl, aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, alkoxycarbonyl, aralkoxycarbonyl, or on sulfur with oxo or lower alkyl.
• heterocyclic groups include, without limitation, epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, oxazolidinonyl, and morpholino.
• the heterocyclic group is fused to an aryl, heteroaryl, or cycloalkyl group. Examples of such fused heterocyles include, without limitation, tetrahydroquinoline and dihydrobenzofuran. Specifically excluded from the scope of this term are compounds having adjacent annular O and/or S atoms.
• heteroaryl refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to three heteroatoms per ring selected from the group consisting of N, O, and S.
• a “heteroaralkyl” or “heteroarylalkyl” group comprises a heteroaryl group covalently linked to an alkyl group, either of which is independently optionally substituted or unsubstituted.
• Preferred heteroalkyl groups comprise a C1-C6 alkyl group and a heteroaryl group having 5, 6, 9, or 10 ring atoms.
• heteroaralkyl groups include pyridylmethyl, pyridylethyl, pyrrolylmethyl, pyrrolylethyl, imidazolylmethyl, imidazolylethyl, thiazolylmethyl, and thiazolylethyl.
• heterocyclyls and heteroaryls include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-l,5,2-dithiazinyl, dihydrofuro[2,3b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indo
• a moiety e.g., cycloalkyl, hydrocarbyl, aryl, heteroaryl, heterocyclic, urea, etc.
• a moiety e.g., cycloalkyl, hydrocarbyl, aryl, heteroaryl, heterocyclic, urea, etc.
• the group optionally has from one to four, preferably from one to three, more preferably one or two, non-hydrogen substituents.
• Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular— CH— substituted with oxo is— C(O)— ), nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl,
• arylcarbamoyl aminoalkyl, acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, and ureido groups.
• halogen refers to chlorine, bromine, fluorine, or iodine.
• acyl refers to an alkylcarbonyl or arylcarbonyl substituent.
• acylamino refers to an amide group attached at the nitrogen atom (i.e., R— CO— NH— ).
• carbamoyl refers to an amide group attached at the carbonyl carbon atom (i.e., NH 2 — CO— ).
• the nitrogen atom of an acylamino or carbamoyl substituent is optionally additionally substituted.
• sulfonamido refers to a sulfonamide substituent attached by either the sulfur or the nitrogen atom.
• amino is meant to include NH 2 , alkylamino, arylamino, and cyclic amino groups.
• ureido refers to a substituted or unsubstituted urea moiety.
• a moiety that is substituted is one in which one or more hydrogens have been independently replaced with another chemical substituent.
• substituted phenyls include 2-flurophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2- fluor-3-propylphenyl.
• substituted n-octyls include 2,4 dimethyl-5-ethy-octyl and 3-cyclopentyl-octyl. Included within this definition are methylenes (— CH 2 — ) substituted with oxygen to form carbonyl-CO— ).
• an "unsubstituted” moiety as defined above e.g., unsubstituted cycloalkyl, unsubstituted heteroaryl, etc. means that moiety as defined above that does not have any of the optional substituents for which the definition of the moiety (above) otherwise provides.
• an "aryl” includes phenyl and phenyl substituted with a halo
• "unsubstituted aryl” does not include phenyl substituted with a halo.
• alkyl or a suitable leaving group e.g., Y can be reacted with 2-chloro-
• compounds of general formula 3 can be treated with a suitable amine, e.g., benzylamine or 1 , 2,3, 4-tetrahydroisoquino line to afford compounds of general structure 6.
• a suitable amine e.g., benzylamine or 1 , 2,3, 4-tetrahydroisoquino line
• Compounds of general structure 6 can be treated with a suitable reducing agent, e.g., a silane such as triethylsilane and an acid such as trifluoroacetic acid to provide compounds of general structure 5.
• a suitable reducing agent e.g., a silane such as triethylsilane and an acid such as trifluoroacetic acid
• compounds of general formula 1 can be reacted with 2-chloro-l ,3-thiazole and a base, e.g., n-BuLi or sec-BuLi to afford compounds of general structure 7.
• a base e.g., n-BuLi or sec-BuLi
• Compounds of general structure 7 can be treated with a suitable amine as described above for Schemes 1 and 2 to provide compounds of general structure 8.
• Compounds of general formula 6 can be treated as described above to provide compound of general formula 5.
• compounds of general formula 6 can be treated with a suitable acid in the presence or absence of a co-reagent to provide compounds of general formula 7.
• Suitable acids can be organic, e.g., trifluoroacetic acid, or mineral, e.g., HC1 or H 2 S0 4 .
• a co- reagent can be a silane, e.g., triethylsilane.
• Compound of general structure 7 can be reduced using suitable conditions, e.g., H 2 in the presence of a suitable catalyst, e.g., Pd/C or Pd(OH)- 2 /C. It will be recognized that compounds of general structure 7 are identical to compounds of Formula I where R 2 is alkenyl. It will be recognized that compounds of general structure 8 are identical to compounds of Formula I where R 2 is lower straight chain or branched alkyl.
• compounds of general formula 3 can be treated with a suitable acid in the presence or absence of a co-reagent to afford compounds of general formula 9 as described above for the preparation of compounds of general structure 7 illustrated in
• Example 1 1HNMR (CDC1 3 , 300 MHz) ⁇ : 2.0-2.2 (s, 3 H), 4.1-4.2 (s, 1 H), 7.3-7.4 (s, 1 H), 7.8-7.9 (d, 1 H), 8.0-8.1 (d, 1 H), 8.2-8.3 (s, 1 H), 8.8 (m, 1 H), 9.0 (s, 1 H), 9.3- 9.4(m, 1 H).
• Example 6 To a solution of Example 6 (200mg, 0.538mmol) in MeOH, NaBH 4 (50mg, 1.23mmol) was added at RT and the mixture stirred for 2 h. The mixture was diluted with water and extracted with EA. The extracts were dried over anhydrous Na 2 S0 4 , filtered and concentrated to give 150mg of Example 5.
• Example 5 To a solution of Example 5 (150mg, 0.4 mmol) in DCE (20 mL) was added TES-H (56mg, 0.48 mmol), the mixture cooled to 0 °C and TFA (3.7 g, 32.8 mmol) was added dropwise at 0 °C. The resulting solution was stirred at 60 °C for 4 hours. The residue was concentrated and purified by silica gel chromatography to afford Example 4 (80 mg).
• Example 7 Procedure: To a solution of 2-chlorothiazole (2.2g, 18.3mmol) in dry THF (10 mL) was added n- BuLi (7.5 mL, 18.3 mmol) dropwise at -78 °C under N 2 and the mixture stirred for 1 h. A solution of Compound 1 (2 g, 16.7 mmol) was added dropwise at -78 ° C. The resulting solution was slowly warmed to RT. The reaction was diluted with NH 4 C1 solution and extracted with EA. The organic extracts were concentrated to give a crude oil. The crude product was purified by silica gel chromatography to afford Compound 2 (2 g).
• Example 14 150 mg, 0.4 mmol
• MeOH MeOH
• Pd/C 20 mg
• the reaction mixture was stirred at RT under a H 2 balloon overnight.
• the residue was filtered, the filter cake washed with MeOH, the filtrate was concentrated and purified by silica gel chromatography to afford Example 13 (40 mg, 27 %).
• Example 18 (35 mg, 35 %).
• Example 23 (33 mg , 4.9 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 2.0-2.1 (m, 2 H), 2.7-2.8 (m, 2 H), 3.8-3.9 (m, 2 H), 4.0-4.1 (s, 2 H), 6.4-6.5 (s, 1 H),6.9-7.0 (m, 1 H), 7.1-7.2 (m,
• Example 24 (77 mg , 10.9 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 1.2-1.3 (d, 8 H), 2.8-3.0 (s, 1 H), 4.0-4.1 (s, 2 H), 4.3-4.5 (s, 2 H), 6.4-6.5 (s, 1 H), 6.9 (s, 1 H), 7.3-7.4 (d, 2 H), 7.6- 7.7 (d, 2 H), 7.7-7.8 (s, 1 H), 7.9 (s, 1 H).
• Example 25 (33 mg , 4.8 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 1.6-1.8 (m, 8 H), 1.8-1.9 (m, 3 H), 3.2-3.3 (m, 1 H), 3.4-3.5 (m, 2 H), 3.7-3.8 (m, 3 H), 4.0 (s, 3 H), 4.6-4.7 (s, 3 H), 6.4-6.5 (s, 1 H), 6.9 (s, 1H), 7.2-7.4 (m, 2 H), 7.6-7.7 (d, 2 H), 7.7-7.8 (s, 1 H), 7.9 (s, 1 H).
• Example 26 (150 mg , 22.8 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 1.5 (m, 3 H), 3.9-4.0 (d, 1 H), 4.5-4.6 (m, 1 H), 5.2-5.3 (m, 1 H), 5.5-5.7 (m, 1 H),6.4-6.50 (s, 1 H), 6.8-6.9 (s, 1 H), 7.4-7.5 (s, 5 H), 7.6-7.7 (d, 1H), 7.7-7.8 (s, 1 H), 7.9 (s, 1 H), 8.2-8.3 (s, 1 H).
• Example 27 (44 mg , 6.7 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 3.4-3.5 (m, 4 H), 3.8-3.9 (m, 4 H), 4.0-4.1 (s, 2 H), 6.5 (s, 1 H), 7.0 (s, 1 H),7.3-7.4 (m, 2 H), 7.6-7.7 (d, 1 H), 7.7- 7.8 (s, 1 H), 7.9-8.0 (s, 1H).
• Example 28 (32 mg , 4.4 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 3.0 (m, 2 H), 3.7-3.8 (m, 2 H), 4.0-4.1 (s, 2 H), 6.5 (s, 1 H), 7.0 (s, 1 H), 7.3-7.4 (m, 4 H), 7.4-7.5 (s, 1 H), 7.4-7.5 (s, 4 H), 7.6-7.7 (s, 1H), 7.6-7.7 (d, 1 H), 7.7-7.8 (s, 1 H), 7.9-8.0 (s, 1H).
• Example 29 (270 mg , 42.9 %).
• Example 30 (146.5 mg , 22.75 " ⁇ 'rlNMR (CDC1 3 , 300 MHz) ⁇ : 1.1-1.2 (d, 6 H), 3.6- 3.7 (m, 2 H), 3.9 (m, 2 H), 4.0-4.1 (s, 2 H), 4.2-4.3 (m, 2 H),4.5 (m, 1 H), 6.5 (s, 1 H), 6.9--7.0 (s, 1 H), 7.1-7.2 (d, 1 H), 7.4 (d, 1 H), 7.5-7.6 (d, 2 H), 7.7-7.8 (s, 1 H), 7.9-8.0 (s, 1 H).
• Example 31 (55 mg, 8.1 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 1.9-2.0 (m, 2 H), 2.7-2.8 (m, 2 H), 3.8-3.9 (m, 2 H), 4.0-4.1 (s, 2 H), 6.4-6.5 (s, 1 H), 6.9-7.0 (m, 1 H), 7.1-7.2 (m, 3 H), 7.3-7.4 (m, 1 H), 7.5-7.6 (d, 2 H), 7.7-7.8 (m, 2 H), 7.9 (s, 1 H).
• Example 32 (68 mg , 9.6 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 1.2-1.3 (d, 8 H), 2.8-3.0 (s, 1 H), 4.0-4.1 (s, 2 H), 4.3-4.5 (s, 2 H), 6.4-6.5 (s, 1 H), 6.9 (s, 1 H), 7.3-7.4 (m, 5 H), 7.4-7.5 (m, 1 H), 7.6-7.7 (d, 2 H), 7.7-7.8 (s, 1 H), 7.9 (s, 1 H).
• Example 33 (171 mg , 24.7 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 1.7-1.9 (m, 8 H), 1.8-1.9 (m, 3 H), 3.2-3.3 (m, 1 H), 3.4-3.5 (m, 2 H), 3.7-3.8 (m, 3 H), 3.9-4.1 (s, 3 H), 6.4-6.5 (s,
• Example 35 (37 mg , 6.2 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 3.4-3.5 (m, 4 H), 3.8 (m, 4 H), 4.0-4.1 (s, 2 H), 6.5 (s, 1 H), 7.0 (s, 1 H),7.1-7.2 (d, 1 H), 7.3-7.5 (m, 2 H), 7.5-7.7 (m, 2 H), 7.7-7.8 (s, 1 H), 7.9-8.0 (s, 1H).
• Example 36 (32.5 mg , 4.5 %) ! HNMR (CDC1 3 , 300 MHz) ⁇ : 3.0 (m, 2 H), 3.7-3.8 (m, 2 H), 4.0-4.1 (s, 2 H), 6.6-4.8 (m, 1 H), 6.5 (s, 1 H), 7.0 (s, 1 H), 7.1-7.2 (s, 1 H), 7.4-7.6 (s, 4 H), 7.7-7.8 (s, 1 H), 7.9-8.0 (s, 1H).
• HCMV cytomegalovirus
• HCMV human cytomegalovirus
• Human MRC5 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10 % fetal bovine serum (FBS) and infected with an HCMV variant expressing GFP tagged pUL99 (the product of late viral UL99 gene) at a multiplicity of 1 infectious unit (IU) per cell.
• DMEM Dulbecco's Modified Eagle Medium
• FBS fetal bovine serum
• GFP tagged pUL99 the product of late viral UL99 gene
• Virus yield in the culture supernatant was determined at 96 hours after infection by infecting fresh MRC5 cells and assaying viral IE1 protein expression. Results were plotted using either Prism Software or CDD Vault (CDD Vault was developed by Collaborative Drug Discovery, Inc., 1633 Bayshore Hwy, Suite 342, Burlingame, CA 94010) in order to calculate IC50s.
• antiviral efficacy of some compounds was assessed by inhibition of HCMV replication during in vitro replication assays. Briefly, confluent monolayers of MRC5 fibroblasts in a 96 well plate format ( ⁇ 1.0 x 10 A 4 cells/well) were infected with an AD 169 strain of HCMV for one hour. After the initial incubation hour, virus containing media was removed and lOOul of media with sequential dilutions of FORGE compounds added to each well. The concentrations of the FORGE compounds were 50 ⁇ , 25 ⁇ , 12.5 ⁇ , 6.25 ⁇ , 3.125 ⁇ , 1.56 ⁇ , and 0.78125 ⁇ as well as a vehicle control (0.5% DMSO). The concentration of DMSO was constant between all conditions.
• Example 24 > 50 ⁇
• Example 34 > 50 ⁇

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Virology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• General Physics & Mathematics (AREA)
• Physics & Mathematics (AREA)
• Finance (AREA)
• Business, Economics & Management (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Computer Networks & Wireless Communication (AREA)
• Biotechnology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Devices For Checking Fares Or Tickets At Control Points (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=55955245

Family Applications (1)

Country Status (10)

Cited By (4)

Families Citing this family (1)

Citations (9)

Family Cites Families (7)

• 2015
  • 2015-11-09 MX MX2017006043A patent/MX377327B/es active IP Right Grant
  • 2015-11-09 CN CN201580071073.2A patent/CN107438435B/zh active Active
  • 2015-11-09 JP JP2017526068A patent/JP6698083B2/ja active Active
  • 2015-11-09 EP EP15859814.4A patent/EP3218373B1/en active Active
  • 2015-11-09 AU AU2015346657A patent/AU2015346657B9/en active Active
  • 2015-11-09 ES ES15859814T patent/ES2820585T3/es active Active
  • 2015-11-09 IL IL308138A patent/IL308138A/en unknown
  • 2015-11-09 US US15/525,504 patent/US10556894B2/en active Active
  • 2015-11-09 WO PCT/US2015/059746 patent/WO2016077232A2/en not_active Ceased
  • 2015-11-09 IL IL252190A patent/IL252190B2/en unknown
  • 2015-11-09 CA CA2967316A patent/CA2967316C/en active Active
• 2019
  • 2019-12-22 US US16/724,343 patent/US11358961B2/en active Active
• 2022
  • 2022-01-13 US US17/574,884 patent/US20220135556A1/en active Pending
• 2024
  • 2024-01-30 US US18/426,855 patent/US20250174051A1/en active Pending

Patent Citations (9)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events